SAN DIEGO, April 16, 2014 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCBB:INNV) today announced that it will exhibit Zestra®, its topical over-the-counter ("OTC") product for female sexual arousal and desire at the 2014 annual American Congress of Obstetricians and Gynecologists clinical meeting in Chicago. The meeting will be held from April 26-30, 2014 with exhibits from April 28-30 at McCormick Place Convention Center. Innovus will be presenting the clinical benefits of Zestra® at its booth #1038 during the exhibition.
Zestra® is the only OTC natural product clinically proven in two U.S. double-blind, placebo controlled trials in 276 women to increase arousal, desire and reduce pain during sexual intercourse. Zestra® is commercialized in the U.S. and Canada and has sold millions of units since its launch in 2007
The American Congress of Obstetricians and Gynecologists ("ACOG"), formerly the American College of Obstetricians and Gynecologists, is a professional association of medical doctors specializing in obstetrics and gynecology in the United States. It has a membership of over 55,000 and represents ninety percent (90%) of the U.S. board-certified obstetrician-gynecologists according to the ACOG website at www.acog.org
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in the OTC male and female sexual dysfunction products. The Company generates revenues from its lead products Zestra® for female arousal, and EjectDelay™ for premature ejaculation, and has a total of four marketed products in this space including CIRCUMSerum™ (for sales outside the U.S. only) and Zestra® Glide.
For more information, go to www.innovuspharma.com.
INNOVUS PHARMA'S FORWARD-LOOKING Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority relating to such products such as Zestra®, to successfully commercialize such products, and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
CONTACT: Innovus Pharma Contact: Kevin Holmes Chesapeake Group email@example.com T: 410-825-3930Source:Innovus Pharmaceuticals, Inc.